Literature DB >> 17517649

Broadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-opening mechanism.

Seung-Wook Chi1, Cheol-Young Maeng, Seung Jun Kim, Mee Sook Oh, Chun Jeih Ryu, Sang Jick Kim, Kyou-Hoon Han, Hyo Jeong Hong, Seong Eon Ryu.   

Abstract

The humanized monoclonal antibody HzKR127 recognizes the preS1 domain of the human hepatitis B virus surface proteins with a broadly neutralizing activity in vivo. We present the crystal structures of HzKR127 Fab and its complex with a major epitope peptide. In the complex structure, the bound peptide forms a type IV beta-turn followed by 3(10) helical turn, the looped-out conformation of which provides a structural basis for broad neutralization. Upon peptide binding, the antibody undergoes a dramatic complementarity determining region H3 lid opening. To understand the structural implication of the virus neutralization, we carried out comprehensive alanine-scanning mutagenesis of all complementarity determining region residues in HzKR127 Fab. The functional mapping of the antigen-combining site demonstrates the specific roles of major binding determinants in antigen binding, contributing to the rational design for maximal humanization and affinity maturation of the antibody.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517649      PMCID: PMC1890477          DOI: 10.1073/pnas.0701279104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

2.  An 80-kilodalton protein that binds to the pre-S1 domain of hepatitis B virus.

Authors:  C J Ryu; D Y Cho; P Gripon; H S Kim; C Guguen-Guillouzo; H J Hong
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

3.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities.

Authors:  R M Esnouf
Journal:  J Mol Graph Model       Date:  1997-04       Impact factor: 2.518

Review 4.  The molecular biology of the hepatitis B viruses.

Authors:  D Ganem; H E Varmus
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

5.  A mutational analysis of binding interactions in an antigen-antibody protein-protein complex.

Authors:  W Dall'Acqua; E R Goldman; W Lin; C Teng; D Tsuchiya; H Li; X Ysern; B C Braden; Y Li; S J Smith-Gill; R A Mariuzza
Journal:  Biochemistry       Date:  1998-06-02       Impact factor: 3.162

Review 6.  Structure of anti-peptide antibody complexes.

Authors:  I A Wilson; J B Ghiara; R L Stanfield
Journal:  Res Immunol       Date:  1994-01

7.  Large surface proteins of hepatitis B virus containing the pre-s sequence.

Authors:  K H Heermann; U Goldmann; W Schwartz; T Seyffarth; H Baumgarten; W H Gerlich
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

8.  Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective.

Authors:  A R Neurath; B Seto; N Strick
Journal:  Vaccine       Date:  1989-06       Impact factor: 3.641

9.  Construction, affinity maturation, and biological characterization of an anti-tumor-associated glycoprotein-72 humanized antibody.

Authors:  Sun Ok Yoon; Tae Sup Lee; Sang Jick Kim; Myung Hee Jang; Young Jun Kang; Jae Hyun Park; Keun-Soo Kim; Hyun Sil Lee; Chun Jeih Ryu; Noreen R Gonzales; Syed V S Kashmiri; Sang Moo Lim; Chang Woon Choi; Hyo Jeong Hong
Journal:  J Biol Chem       Date:  2006-01-09       Impact factor: 5.157

10.  Cloning and expression of a novel hepatitis B virus-binding protein from HepG2 cells.

Authors:  S De Falco; M G Ruvoletto; A Verdoliva; M Ruvo; A Raucci; M Marino; S Senatore; G Cassani; A Alberti; P Pontisso; G Fassina
Journal:  J Biol Chem       Date:  2001-06-01       Impact factor: 5.157

View more
  11 in total

1.  Structure and design of broadly-neutralizing antibodies against HIV.

Authors:  Seong Eon Ryu; Wayne A Hendrickson
Journal:  Mol Cells       Date:  2012-06-25       Impact factor: 5.034

Review 2.  Antibody-Mediated Catalysis in Infection and Immunity.

Authors:  Anthony Bowen; Maggie Wear; Arturo Casadevall
Journal:  Infect Immun       Date:  2017-08-18       Impact factor: 3.441

3.  Pre-structured motifs in the natively unstructured preS1 surface antigen of hepatitis B virus.

Authors:  Seung-Wook Chi; Do-Hyoung Kim; Si-Hyung Lee; Iksoo Chang; Kyou-Hoon Han
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

4.  De novo design of modular and tunable protein biosensors.

Authors:  Alfredo Quijano-Rubio; Hsien-Wei Yeh; Jooyoung Park; Hansol Lee; Robert A Langan; Scott E Boyken; Marc J Lajoie; Longxing Cao; Cameron M Chow; Marcos C Miranda; Jimin Wi; Hyo Jeong Hong; Lance Stewart; Byung-Ha Oh; David Baker
Journal:  Nature       Date:  2021-01-27       Impact factor: 49.962

5.  Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure.

Authors:  Miroslaw K Gorny; Jared Sampson; Huiguang Li; Xunqing Jiang; Maxim Totrov; Xiao-Hong Wang; Constance Williams; Timothy O'Neal; Barbara Volsky; Liuzhe Li; Timothy Cardozo; Phillipe Nyambi; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

6.  Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis.

Authors:  Kathryn E Tiller; Ratul Chowdhury; Tong Li; Seth D Ludwig; Sabyasachi Sen; Costas D Maranas; Peter M Tessier
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

Review 7.  Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.

Authors:  Yueran Yu; Shangda Li; Weifeng Liang
Journal:  Emerg Microbes Infect       Date:  2018-07-26       Impact factor: 7.163

8.  A potent human neutralizing antibody Fc-dependently reduces established HBV infections.

Authors:  Dan Li; Wenhui He; Ximing Liu; Sanduo Zheng; Yonghe Qi; Huiyu Li; Fengfeng Mao; Juan Liu; Yinyan Sun; Lijing Pan; Kaixin Du; Keqiong Ye; Wenhui Li; Jianhua Sui
Journal:  Elife       Date:  2017-09-26       Impact factor: 8.140

Review 9.  Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology.

Authors:  John A Robinson
Journal:  J Pept Sci       Date:  2013-01-24       Impact factor: 1.905

10.  Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies.

Authors:  Tetyana Dashivets; Jan Stracke; Stefan Dengl; Alexander Knaupp; Jan Pollmann; Johannes Buchner; Tilman Schlothauer
Journal:  MAbs       Date:  2016-09-09       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.